Retatrutide
Triple GLP-1/GIP/glucagon receptor agonist studied in metabolic research models.
This product is not a drug, food, or cosmetic and is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. By purchasing, you confirm you are a qualified researcher or institution acquiring this product solely for in-vitro laboratory research. See our Research Disclaimer for full terms.
Description
Retatrutide (LY3437943) is a synthetic peptide conjugated to a fatty diacid moiety that simultaneously activates the GLP-1, GIP, and glucagon receptors — the most advanced triple-agonist candidate in current metabolic research. Cell-based assays indicate greater potency at the GIP receptor relative to native ligands, with partial agonism at GLP-1R and the glucagon receptor. Phase 2 clinical research (NEJM, 2023) reported dose-dependent weight reduction over a 48-week study period. Supplied for in-vitro laboratory research only — not for human or veterinary use.